---
figid: PMC7021580__nihms-1062935-f0003
figtitle: MED12 and Cancer Drug Resistance
organisms:
- Homo sapiens
- Mus musculus
- Saccharomyces cerevisiae
pmcid: PMC7021580
filename: nihms-1062935-f0003.jpg
figlink: pmc/articles/PMC7021580/figure/F3/
number: F3
caption: In the canonical TGF-β pathway, TGF-βR2 activates TGF-βR1, which in turn
  phosphorylates Smad2 and Smad3. Smad2 and Smad3 then translocate to the nucleus
  and regulate the expression of TGF-β target genes. TGF-β signaling induces EMT through
  the phosphorylation of β-catenin, leading to the up-regulation of Snail, vimentin,
  and N-cadherin. Loss of MED12 causes drug resistance by increasing the level of
  TGFβR2, which activates the ERK and SMAD pathways. This leads to cell proliferation
  and features of EMT. Additionally, methylation of MED12 by CARM1 renders cancer
  cells sensitive to chemotherapy drugs through suppression of p21 transcription.
papertitle: The Emerging Role of Mediator Complex Subunit 12 in Tumorigenesis and
  Response to Chemotherapeutics.
reftext: Shengjie Zhang, et al. Cancer. ;126(5):939-948.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9603769
figid_alias: PMC7021580__F3
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
- Saccharomyces cerevisiae S288C
redirect_from: /figures/PMC7021580__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7021580__nihms-1062935-f0003.html
  '@type': Dataset
  description: In the canonical TGF-β pathway, TGF-βR2 activates TGF-βR1, which in
    turn phosphorylates Smad2 and Smad3. Smad2 and Smad3 then translocate to the nucleus
    and regulate the expression of TGF-β target genes. TGF-β signaling induces EMT
    through the phosphorylation of β-catenin, leading to the up-regulation of Snail,
    vimentin, and N-cadherin. Loss of MED12 causes drug resistance by increasing the
    level of TGFβR2, which activates the ERK and SMAD pathways. This leads to cell
    proliferation and features of EMT. Additionally, methylation of MED12 by CARM1
    renders cancer cells sensitive to chemotherapy drugs through suppression of p21
    transcription.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFB1
  - TGFB2
  - TGFB3
  - EGF
  - MED12
  - EGFR
  - TGFBR1
  - KRAS
  - HRAS
  - NRAS
  - SMAD2
  - SMAD3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - CTNNB1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - SMAD4
  - MAPK3
  - MAPK1
  - SNAI1
  - CDH2
  - MED23
  - ELK1
  - KCNH4
  - KCNH8
  - ITK
  - SLC22A3
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - CARM1
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - ERVW-4
  - Tgfb1
  - Ltbp1
  - Egf
  - Med12
  - Egfr
  - Tgfbr1
  - ras
  - Hras
  - Kras
  - Rem1
  - Smad2
  - Smad3
  - Zhx2
  - Ctnnb1
  - Mdk
  - Smad4
  - Mapk3
  - Mapk1
  - Snai1
  - Cdh2
  - Med23
  - Elk1
  - Itk
  - Slc22a3
  - Carm1
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - Mela
  - Gm42368
  - SRB8
  - SNA2
  - POL2
  - Gefitinib
---
